Vantage Isotopes
Vantage Isotopes Revenue Share
A share of metered output from an operating actinium-225 and molybdenum-99 production line.
Actinium-225 is one of the scarcest useful substances on earth and targeted alpha therapy demand is growing faster than supply. Vantage operates an accelerator-driven subcritical target that has been shipping for two years under three take-or-pay distribution agreements. Investors receive 4% of gross isotope revenue until a 1.9x cap, paid quarterly against metered output.
$5,000,000 committed of $5,000,000
$5,000,000 released · 100% subscribed
- Minimum
- $100
- Instrument
- Revenue share
- Term
- 10 yr
- Investors
- 2,766
$50 per unit
Closed April 30, 2026
Sign in to see your limit
- Eligibility depends on residency, accreditation status and how much you have already invested this year.
- You can read everything about this offering without an account. Committing capital requires one.
Demo · viewing as
Browsing without an account. Everything is visible; nothing is purchasable until you verify who and where you are.
Or answer the questions yourselfNo money will move
No payment processor is connected. The commitment flow runs end to end, through amount, agreement, signature and receipt, and records a simulated position rather than a charge.
TRL assessment
9
Technology readiness level, 1 to 9
Confidence band 8.8 – 9.0
The facility has been in commercial operation for two years and the evidence is metered output and shipped product rather than analysis. This is the narrowest band on the platform because there is nothing left to infer. The residual risk in this offering is market and reimbursement policy, not technology.
At TRL 9, the ladder permits Revenue share or Fixed-rate note or Municipal mini-bond and releases up to 100% of committed capital. This offering is structured as a revenue share, which is consistent with that band.
Signed and published
- Reviewer
- Dr. Samuel Adeyemi
- Credential
- PhD Nuclear Engineering; ASME Section III reviewer
- Signed
- May 15, 2026
- Published
- May 16, 2026
- Methodology
- v1.4
- Model
- ci-trl-2026.06
- Generated
- May 11, 2026
Evidence
Every score cites the documents it was derived from, with the weight each carried. An assessment without evidence is an opinion.
| Source | Document | Date | Weight |
|---|---|---|---|
| Metered output | Two years of production and shipment records Issuer operating records, distributor confirmations Cumulative shipped activity across 118 production runs with 94% schedule adherence. | Apr 30, 2026 | 42% |
| Operating license | Materials license, in good standing NRC materials license with no open violations Most recent inspection closed with no findings. | Feb 14, 2026 | 24% |
| Supplier contract | Three take-or-pay distribution agreements Radiopharmacy distributors, multi-year terms Contracted volume exceeds current production capacity. | Nov 8, 2025 | 22% |
| Peer-reviewed publication | Target yield and separation efficiency Peer-reviewed radiochemistry literature Independent replication of separation yield within stated tolerance. | May 19, 2025 | 12% |
Score history
A score changes on the day a reviewer signs a new assessment, which is why this is a step line rather than a curve.